Refine by
Cell Genomics Articles & Analysis
23 news found
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer ...
She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. To address this challenge, we have brought to market our CytoR1 Platform - a label-free, fully-integrated product system for ...
(Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18th Annual PEGS Boston Conference, a protein engineering and cell therapy summit, being held virtually and in person from May 2-6, 2022 at the Hynes Convention Center. ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. The ...
CytoRecovery, Inc., a leader in the marker free enrichment, sorting, and recovery of live cells, presented recent study results at the American Association for Cancer Research (AACR) Annual Meeting 2022 currently being held in New Orleans. The study was completed in collaboration with The Laboratory of Integrative Cancer Immunology, National Cancer Institute (NCI/NIH Bethesda, MD) and Virginia ...
Abud notably developed one of the first methods to generate human microglia from stem cells, showing their functional genomics and how they play a role in health and disease. ...
Our approach is to combine best-in-class single-cell genomic methods and artificial intelligence with a deep understanding of immunology.” Immunai has leveraged its best-in-class proprietary technologies and more than 25 academic partnerships to build AMICA™, the Annotated Multiomic Immune Cell Atlas, the world’s largest data ...
ByImmunai
AMICA is a downloadable database of annotated multi-omic immune cells that includes information about gene expression, proteins, T-cell and B-cell receptors for immune cells, clinical and/or lab data, and a downloadable artificial intelligence software platform designed for characterizing and analyzing immune ...
ByImmunai
DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. ...
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission ...
“Our objective is to use authentic cells, to have them integrate entirely into the brain and restore lost physiologic function. ...
Genetically engineered induced pluripotent stem cells (iPSCs) provide a highly consistent and unlimited source for allogeneic cell therapies. ...
Immunai’s end-to-end platform combines the latest advances in single-cell genomics, bioinformatics, and artificial intelligence to measure the immune system at high resolution, at an unprecedented scale. ...
ByImmunai
Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. ...
Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics. Previously backed by Y Combinator, the San Francisco-based Dropprint aims to provide big data and machine learning ...
ByImmunai
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. ...
ByImmunai
The Dropprint acquisition is key to this effort in that it brings Immunai technologies that will help it scale its single-cell genomics analyses. The San Francisco-based company has developed software tools for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of ...
ByImmunai
Immunai will also extend its functional genomics capabilities to reprogram immune cells and validate targets to better support discovery, prioritization, and development of new therapies and drug combinations. ...
ByImmunai
Jonathan Gershoni of TAU’s School of Molecular Cell Biology and Biotechnology. The agreement grants Neovii the exclusive right to develop and commercialize a novel and recently patented platform technology conceived by Prof. ...